I REFI	JAN 3 0 200	()	PTO/SB/21 (08-
Ē	E	pplication Number	10/001,221
TRANSMITT	AK BADEMABY	Filing Date	October 30, 2001
FORM		First Named Inventor	Schall, Thomas J.
(to be used for all correspondence a	after initial filing)	Art Unit	1642
		Examiner Name	Canella, Karen A.
Total Number of Pages in This Submission		Attorney Docket Number	019934-004100US
	ENC	LOSURES (Check all that a	pply)
Fee Transmittal Form	☐ Drawin	ng(s)	After Allowance Communication to Group
Fee Attached	Licens	ing-related Papers	Appeal Communication to Board of Appea and Interferences
Amendment/Reply	Petition	n	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final	, 	n to Convert to a ional Application	Proprietary Information
Affidavits/declaration(s)	Power Chang	of Attorney, Revocation e of Correspondence Address	Status Letter
Extension of Time Request	☐ Termin	nal Disclaimer	Other Enclosure(s) (please identify below):
Express Abandonment Request		st for Refund umber of CD(s)	Return Postcard, copies of thirty-one (31) cited references
Information Disclosure Stateme	nt		
Certified Copy of Priority Document(s)	Rema	1	is authorized to charge any additional fees to Depos
Response to Missing Parts/ Incomplete Application			
Response to Missing Parts under 37 CFR 1.52 or 1.53			
		F APPLICANT, ATTORNI	EY, OR AGENT
or Scott I Aus	nd Townsend a		. No. 42,271
individual A	(\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	. 140. 42,271
Signature	Ululei	lal	
Date 01-28	-04		
	CERTIFIC	ATE OF TRANSMISSION	/MAILING
hereby certify that this correspondence is to sirst class mail in an envelope addressed	eing facsimile trans to: Commissioner fo	mitted to the USPTO or deposited or Patents, P.O. Box 1450, Alexan	with the United States Postal Service with sufficient postagoria, VA 22313-1450 on the date shown below.
	1. Wartell	· · · · · · · · · · · · · · · · · · ·	
Signature , M	0	. D. J. M	Date
IUN	WeN	Ditrocu	1/28/04

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT

Attorney Docket No.: 019934-004100US

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

1005 BS NAV 2004

TOWNSEND and TOWNSEND and CREW LLP

y: Xule MU Nikole M. Wartell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thomas J. Schall

Application No.: 10/001,221

Filed: October 30, 2001

For: METHODS AND COMPOSITIONS

FOR INDUCING AN IMMUNE

RESPONSE

Examiner: Canella, Karen A.

Art Unit: 1642

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Thomas J. Schall

Application No.: 10/001,221

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Scott L. Ausenhus Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 303-571-4000 Fax: 303-571-4321

SLA:nmb 60126179 v1

JAN 3 0 ZIPS LESSIN

RADEW P

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	•			_
Sheet	1	of	3	

	Complete if Known
Application Number	10/001,221
Filing Date	October 30, 2001
First Named Inventor	Schall, Thomas J.
Art Unit	1642
Examiner Name	Canella, Karen A.
Attorney Docket Number	019934-004100US

	U.S. PATENT DOCUMENTS+						
Document Number							
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	A1	US-5,141,867	08-25-1992	Ivanoff et al.			
	A2	US-5,705,151	01-06-1998	Dow et al.			
	A3	US-5,837,247	11-17-1998	Oppenheim et al.			
	A4	US-5,935,568	08-10-1999	Dow et al.			

				FOREIGN	PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Fore	eign Patent Docum Number ⁴	ent Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	РСТ	WO 94/28916	A1	12-22-1994	British Biotech Pharmaceuticals Limited		
	B2	PCT	WO 96/11279	A2	04-18-1996	Government of the United States - Department of Health and Human Services		
	В3	PCT	WO 96/36366	A1	11-21-1996	National Jewish Center for Immunology and Respiratory Medicine		
	B4	PCT	WO 97/19696	A1	06-05-1997	Lusso, Paolo; Gallo, Robert C.; Cocchi, Fiorenza; DeVico, Anthony; Garzino-Demo, Alfredo		
	B5	PCT	WO 98/15285	A1	04-16-1998	The Wistar Institute of Anatomy and Biology		
	В6	PCT	WO 99/43839	A1	09-02-1999	Trustee of the University of Pennsylvania		
	В7	PCT	WO 99/53960	A2	10-28-1999	Chiron Corp.		
	B8	PCT	WO 00/22124	A2	04-20-2000	Canji, Inc.		
	B9	PCT	WO 01/80882	A3	11-01-2001	ChemoCentryx, Inc.		

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

60126179 v1

Sepstitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	1400 40 1114119	J		Jou. 37
Sheet	2	of	1 3	

Complete if Known				
Application Number	10/001,221			
Filing Date	October 30, 2001			
First Named Inventor	Schall, Thomas J.			
Art Unit	1642			
Examiner Name	Canella, Karen A.			
Attorney Docket Number	019934-004100US			

	1	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	C1	BANCHEREAU, JACQUES and RALPH M. STEINMAN; Dendritic cells and the control of immunity; Nature; 19 March, 1998; pp. 245-252; Vol. 392	
	C2	CAUX, CHRISTOPHE, et al.; Developmental Pathways of Human Myeloid Dendritic Cells; Dendritic Cells: Biology and Clinical Applications; 1999; pp. 63-92 (chapter 5); Academic Press	
	C3	ChemoTx Disposable; Neuro Probe website; Products (1 page) and Protocols (2 pages); Wednesday, April 19, 2000; http://www.neuroprobe	
	C4	CHOW, YEN-HUNG, et al.; Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes; The Journal of Immunology; 1998; pp. 1320-1329; Vol 160	
	C5	DILLOO, DAGMAR, et al.; Combined chemokine and cytokine gene transfer enhances antitumor immunity; <i>Nature Medicine</i> ; October 1996; pp. 1090-1095; Vol. 2, No. 10	
	C6	ENG, VICKI M., et al.; The Stimulatory Effects of interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon γ In Vivo; <i>J. Exp. Med.</i> ; May 1995; pp. 1893-1898; Vol. 181	
	C7	EO, SEONG KUG, et al.; Modulation of Immunity against Herpes Simplex Virus Infection via Mucosal Genetic Transfer of Plasmid DNA Encoding Chemokines; Journal of Virology; January 2001; pp. 569-578; Vol. 75, No. 2	
	C8	GenBank Accession No. P27784, August 1, 1992	
	C9	KHUDYAKOV, YU E.; et al. Linear B-Cell Epitopes of the NS3-NS4-NS5 Proteins of the Hepatitis C. Virus as Modeled with Synthetic Peptides; <i>Virology</i> ; 1995; pp. 666-672; Vol 206	
	C10	LILJEQVIST, SISSELA & STÅHL, "Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines" Journal of Biotechnology, 1999, pp. 1-33, Vol. 73, Elsevier.	
	C11	MOLDOVEANU, ZINA, et al.; Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins; Vaccine; 1995; pp. 1013-1022; Vol. 13, No. 11	
	C12	ORANGE, JORDAN S.; et al.; Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids; <i>J. Exp. Med.</i> ; March 1995; pp. 901-914; Vol. 181	
	C13	R & D Systems 2000 Catalog; front and back cover, Contents in Brief, Ordering Information, (page i) Contact Information (page ii), Cytokines & Related Molecules (p. 93-94 and 162), Antibodies (p. 163-164 and 291)	
	C14	RAMSHAW, IAN; et al.; Expression of Cytokines by Recombinant Vaccinia Viruses: A Model for Studying Cytokines in Virus Infections in vivo; Immunological Reviews; 1992; pp. 157-182; No. 127	
	C15	TSUJI, T., et al.; HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine; <i>Immunology</i> ; 1997; pp. 1-6; Vol. 90	
Examiner Signature		Date Considered	_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

019934-004100US

Supertute for form 1449B/PTO
INFORMATION D
STATEMENT BY

Sheet

3

of

3

Sulfatute for form 1449B/PTO	Complete if Known				
y	Application Number	10/001,221			
INFORMATION DISCLOSURE	Filing Date	October 30, 2001			
STATEMENT BY APPLICANT	First Named Inventor	Schall, Thomas J.			
	Art Unit	1642			
(use as many sheets as necessary)	Examiner Name	Canella, Karen A.			

Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *			T ²	
	C16	WELLS, JAMES "Additivity of Mutational Effects in Proteins" <i>Biochemistry</i> , September 18, 1990; p. 8509-8517, Vol. 29, No. 37.		
	C17	WU, GEORGE Y., et al.; Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System; The Journal of Biological Chemistry; 1987; pp. 4429-4432; Vol. 262, No. 10		
	C18	XIANG, ZHIQUAN, et al.; Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines; <i>Immunity</i> ; February 1995; pp. 129-135; Vol. 2		

Examiner	Date	•	
Signature	Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.